Metabolism

Savanna Ingredients GmbH Appoints Palmer Holland as Exclusive Distribution Partner

Retrieved on: 
Thursday, April 25, 2024
Psicose, Sucrose, Nutrition, Solubility, GMO, Partnership, Food industry, Metabolism, Cellobiose, Convenience food

CLEVELAND, April 24, 2024 /PRNewswire/ -- Savanna Ingredients GmbH and Palmer Holland, Inc. have signed an exclusive distribution partnership for crystalline Allulose and Cellobiose in the USA and Canada markets.

Key Points: 
  • CLEVELAND, April 24, 2024 /PRNewswire/ -- Savanna Ingredients GmbH and Palmer Holland, Inc. have signed an exclusive distribution partnership for crystalline Allulose and Cellobiose in the USA and Canada markets.
  • "Savanna Ingredients GmbH's value proposition and focus on quality and sustainability aligns well with Palmer Holland's mission to source high-quality natural ingredients designed to meet the needs of tomorrow," said Brendan Michel, Palmer Holland Business Manager - Health and Nutrition.
  • Allulose does not dock in the body, the calories are not metabolized but excreted," said Ralph Cartarius, Managing Director of Savanna Ingredients GmbH.
  • Another promising innovation from Savanna Ingredients GmbH is the functional carbohydrate Cellobiose.

Summit Clinical Research Statement on Co-Founder and Chairman Dr. Stephen Harrison

Retrieved on: 
Thursday, April 25, 2024
FDA, MASH, University, Army, Gastroenterology, Graduate medical education, Ecosystem, Liver disease, University of Oxford, Death, Publishing, Research, Dean (education), Brooke Army Medical Center, Metabolism, Entrepreneurship, Hepatology, Family, Patient, SAN, Medical device

SAN ANTONIO, April 24, 2024 /PRNewswire/ -- Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison.

Key Points: 
  • SAN ANTONIO, April 24, 2024 /PRNewswire/ -- Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison.
  • "Dr. Harrison will be missed more that words can express," said Gail Hinkson, Co-Founder and President of Summit Clinical Research.
  • "Dr. Harrison was proud to tell the story of how we imagined Summit on the back of a napkin and built it into the complex clinical research leader that it is today.
  • Dr. Harrison was the Co-Founder and Chairman of Summit Clinical Research, LLC, and the Founder and Chairman of Pinnacle Clinical Research in San Antonio, Texas, among others.

Endevica Bio drug candidate shows success in weight loss in new study

Retrieved on: 
Tuesday, April 23, 2024
Cancer, Diabetes, Weight loss, ESMO, Research, MC4R, ASCO, Obesity, Patient, Metabolism, Quality of life, Rat, Dietary supplement

Additionally, the treatment of A07D was found to provide durable weight loss even after cessation of treatment – suggesting that this approach avoids the problem of weight loss plateau and weight rebound seen with use of GLP1s alone.

Key Points: 
  • Additionally, the treatment of A07D was found to provide durable weight loss even after cessation of treatment – suggesting that this approach avoids the problem of weight loss plateau and weight rebound seen with use of GLP1s alone.
  • Results from the study support the idea that weight-regulating effects such as those advanced by Endevica Bio to address conditions such as involuntary cancer-related weight loss, can also be harnessed to regulate weight in several disease areas in which excess weight may be detrimental, including diabetes and obesity.
  • Meanwhile, Endevica Bio's most advanced drug candidate in the weight modulation space, TCMCB07 (B07), will be entering Phase 2 studies this summer.
  • "We're thrilled with the research results showing our drug candidate could potentially improve the lives of millions of people who seek to lose weight," said Russell Potterfield, CEO and Executive Chairman of Endevica Bio.

IDTechEx Examines the Opportunities for Wearables in Digital Health

Retrieved on: 
Friday, April 19, 2024
FDA, Sleep apnea, Omron, Sleep disorder, Food, Travel, Health, Dexcom, Diabetes, CGM, Respiratory rate, Medtech, Artificial intelligence, Intelligence, Artificiality, Samsung Galaxy Watch, Digital health, Patient, Electronics, Movement, Metabolism, Athlete, Quality of life, Sleep

IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.

Key Points: 
  • IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.
  • The IDTechEx report on digital health discusses opportunities for consumer health wearables, including key value propositions and a roadmap for wearable sensor technology segmented by key biometrics.
  • IDTechEx's report on digital health covers the intersection of the digital health, diabetes, and consumer markets and includes a 10-year forecast for the CGM market from 2024 – 2034.
  • The consumer health wearables narrative is only one of several stories that IDTechEx covers in " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ".

IDTechEx Examines the Opportunities for Wearables in Digital Health

Retrieved on: 
Friday, April 19, 2024
FDA, Sleep apnea, Omron, Sleep disorder, Food, Travel, Health, Dexcom, Diabetes, CGM, Respiratory rate, Medtech, Artificial intelligence, Intelligence, Artificiality, Samsung Galaxy Watch, Digital health, Patient, Electronics, Movement, Metabolism, Athlete, Quality of life, Sleep

IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.

Key Points: 
  • IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.
  • The IDTechEx report on digital health discusses opportunities for consumer health wearables, including key value propositions and a roadmap for wearable sensor technology segmented by key biometrics.
  • IDTechEx's report on digital health covers the intersection of the digital health, diabetes, and consumer markets and includes a 10-year forecast for the CGM market from 2024 – 2034.
  • The consumer health wearables narrative is only one of several stories that IDTechEx covers in " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ".

JDRF Celebrates Research Award Winners and Recognizes Type 1 Diabetes Research Leaders

Retrieved on: 
Thursday, April 18, 2024
Consensus, University, Type 1 diabetes, Diabetes, Person, Risk, Food, Research, JDRF, Immunotherapy, Endocrinology, Retinopathy, Disease, Indiana University, Medicine, Metabolism, Clinical trial, Petah Tikva, Pediatrics, AID, Medical Center, Pediatric endocrinology, Inborn errors of metabolism, Quality of life, Division, Growth, Pharmaceutical industry

NEW YORK, April 18, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to five outstanding leaders in T1D research whose impact has pushed JDRF's mission forward.

Key Points: 
  • NEW YORK, April 18, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to five outstanding leaders in T1D research whose impact has pushed JDRF's mission forward.
  • She began her career with a JDRF career development award to support one of her first research projects on insulin pump therapy in very young children with diabetes.
  • The award recognizes leaders and innovators of outstanding clinical and translational T1D research.
  • JDRF Research award recipients were recognized at a ceremony in New York City earlier in April 2024.

Baszucki Group Hires Jeff MacGregor as First Chief Communications Officer

Retrieved on: 
Thursday, April 18, 2024
Science, University, SXSW, Chan Zuckerberg Initiative, Agriculture, San Francisco State University, MacGregor, Marketing, Neuroscience, Meta, San Francisco Bay Area, Roblox, Family, Mental health, Rutgers University, CZI, Metabolism, Communication, Chicago International Film Festival, Democracy, Creativity, Advertising, SAN

SAN MATEO, Calif., April 18, 2024 /PRNewswire/ -- Today, Baszucki Group announced that Jeff MacGregor has joined the organization as Chief Communications Officer. In his new role, MacGregor will lead all strategic communications efforts, including media relations, documentary films, and brand management of its metabolic mental health initiative, Metabolic Mind.

Key Points: 
  • Formerly of Chan Zuckerberg Initiative, MacGregor will direct Baszucki Group's media and communications efforts across its metabolic mental health, neuroscience, democracy, and regenerative agriculture portfolios
    SAN MATEO, Calif., April 18, 2024 /PRNewswire/ -- Today, Baszucki Group announced that Jeff MacGregor has joined the organization as Chief Communications Officer.
  • In his new role, MacGregor will lead all strategic communications efforts, including media relations, documentary films, and brand management of its metabolic mental health initiative, Metabolic Mind .
  • "Jeff brings creativity, strategic thinking, and deep experience to communications and advocacy," said Jan Ellison Baszucki, who co-founded Baszucki Group with Roblox founder and CEO, David Baszucki, in 2021.
  • "I'm deeply inspired by Baszucki Group's innovative approach to studying and treating mental health disorders, linking metabolism and brain health for groundbreaking treatments," said Jeff MacGregor.

Canaan Adds Accomplished Executive and Scientist, Uwe Schoenbeck, Ph.D., Along with New Capital, to Bolster its Biopharma Investment Efforts

Retrieved on: 
Wednesday, April 17, 2024
Investment, Cell biology, Boehringer Ingelheim, News, Hospital, Abstract, Cardiology, CTI, WRDM, Partnership, Research, Brigham, Development, Cardiovascular Research, Therapy, Brigham and Women's Hospital, Senior, Science, Translation, Inflammatory bowel disease, Patient, Neurology, Acquisition, Initial public offering, General partnership, Metabolism, Harvard Medical School, Health, Assistant, Emerging, Biotechnology, Pharmaceutical industry

MENLO PARK, Calif., April 17, 2024 /PRNewswire/ -- Canaan, a venture capital firm that invests in entrepreneurs with visionary ideas, announced the addition of Uwe Schoenbeck, Ph.D., to its healthcare investment team as a new Venture Partner. Dr. Schoenbeck's impressive career has spanned more than 25 years in the life science and healthcare industry, as well as academia, providing him with an exceptional global network among leading research institutions, biotechnology and biopharmaceutical companies, and venture firms. He is highly regarded for his contributions in enabling and translating emerging science into breakthrough therapies, reaching from scientific collaborations, licensing, and acquisition deals to venture investing. In joining Canaan's healthcare investment team, Dr. Schoenbeck will help drive new investments and company creation from Canaan XIII, the firm's latest fund, by bringing in deep scientific and pharmaceutical perspectives, while also serving as a valuable resource to companies across the firm's existing biopharma portfolio. To this end, he has already facilitated his first investment as a member of the team, leading Canaan's participation in the recently announced $132 million Series B financing for Alterome Therapeutics and being named a member of the company's board of directors.

Key Points: 
  • Most recently, Dr. Schoenbeck served as Senior Vice President and Chief Scientific Officer Emerging Science & Innovation (ES&I) in Pfizer's Worldwide Research, Development & Medical (WRDM) division.
  • In leading ES&I, he worked to harness external breakthrough science, assets, and technologies by leveraging a broad range of partnering vehicles.
  • "It is not often that we have the opportunity to add someone of Uwe's caliber and track record to the Canaan investment team.
  • In additional news, Canaan today reported that it has expanded the size of its biopharma investment funds with the addition of more than $100 million in new capital.

MigraKet® Brings the World's First Medical Food For Migraine to the U.S

Retrieved on: 
Friday, April 12, 2024
Migraine, Pain, Woman, Doctor of Philosophy, Vitamin, Dehydration, Oxygen, Food, Headache, Metabolism, Antioxidant, Sleep, Injection

BASEL, Switzerland, April 12, 2024 /PRNewswire/ -- International wellness brand Brain Ritual is launching MigraKet®, a revolutionary approach to migraine management developed by renowned neuroscientist and former chronic migraineur, Elena Gross, PhD. With the U.S. release of MigraKet®, sufferers of migraine can anticipate a newfound hope in managing their condition effectively.

Key Points: 
  • With the U.S. release of MigraKet®, sufferers of migraine can anticipate a newfound hope in managing their condition effectively.
  • Different from drugs, painkillers and injections that address migraine symptoms, MigraKet® is the first holistic medical food formulation for the management of a potential root cause of migraine.
  • "We want migraine sufferers to regard their pain as a helpful alarm - alerting them of a critical system breakdown.
  • Chronic migraine is defined as having headache on at least 15 days per month, with eight of these having migraine symptoms, for at least three months.

Try Maggie Q's ActivatedYou Morning Complete to Help Minimize Stress for Stress Awareness Month

Retrieved on: 
Thursday, April 11, 2024
Spend, Nature, Glass, Health, Gymnema, Nutritional science, Water, Life, Yoga, Completeness, Mental health, Happiness, Mindfulness, Probiotic, Metabolism, LOS, Nutrient, Antioxidant, Anxiety, Growth, Meditation, Dietary supplement

LOS ANGELES, April 11, 2024 /PRNewswire/ -- Stress Awareness Month is observed annually in April to raise awareness about the causes and effects of stress, as well as to provide individuals with tools and resources to manage stress effectively. It serves as a reminder to prioritize mental health and well-being in our daily lives.

Key Points: 
  • Maggie Q recommends ActivatedYou® Morning Complete® , a powerful daily wellness drink featuring a custom-selected blend of nutrients designed to help "rev up" your metabolism, keep your spirit lifted, and provide the boost of energy needed to tackle any task.†*
    What is ActivatedYou Morning Complete?
  • Other blends featured in Morning Complete include probiotics, prebiotics, antioxidants, green superfoods, metabolic support, and blends for cellular function and liver support.
  • Maggie Q's ActivatedYou suggests mixing Morning Complete with 8oz of water or iced green tea.
  • ActivatedYou Morning Complete can be purchased from the official ActivatedYou website .